Insmed to Participate in the Stifel Healthcare Conference 2013
04 Septembre 2013 - 2:00PM
Marketwired
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company
focused on developing and commercializing an inhaled anti-infective
to treat patients battling serious lung diseases that are often
life-threatening, today announced that Will Lewis, Insmed's
President and Chief Executive Officer, will deliver a corporate
overview at the upcoming Stifel Healthcare Conference 2013 taking
place September 11-12, 2013 at the Four Seasons Hotel in Boston.
Mr. Lewis will be presenting on September 11th at 2:05 p.m. Eastern
time.
Mr. Lewis' presentation will be webcast live on the internet and
can be accessed by visiting the investors section of the company's
website at www.insmed.com. A replay of the webcast will be archived
on the Insmed website for 90 days following the presentation.
About Insmed Insmed Incorporated is a
biopharmaceutical company dedicated to improving the lives of
patients battling serious lung diseases. Insmed is focused on the
development and commercialization of ARIKACE®, or liposomal
amikacin for inhalation, for at least two identified orphan patient
populations: cystic fibrosis (CF) patients with Pseudomonas
aeruginosa lung infections and patients with non-tuberculous
mycobacteria (NTM) lung infections. For more information, visit
www.insmed.com.
Forward-looking statements: This release
contains forward-looking statements. Words, and variations of
words, such as "intend," "expect," "will," "anticipate," "believe,"
"continue," "propose" and similar expressions are intended to
identify forward-looking statements. Investors are cautioned that
such statements in this release, including statements relating to
the status, results and timing of clinical trials and clinical
data, the anticipated benefits of Insmed's products, the
anticipated timing of regulatory submissions, and the ability to
obtain required regulatory approvals, bring products to market and
successfully commercialize products constitute forward-looking
statements that involve risks and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
without limitation, failure or delay of European, Canadian, U.S.
Food and Drug Administration and other regulatory reviews and
approvals, competitive developments affecting the Company's product
candidates, delays in product development or clinical trials or
other studies, patent disputes and other intellectual property
developments relating to the Company's product candidates,
unexpected regulatory actions, delays or requests, the failure of
clinical trials or other studies or results of clinical trials or
other studies that do not meet expectations, the fact that
subsequent analyses of clinical trial or study data may lead to
different (including less favorable) interpretations of trial or
study results or may identify important implications of a trial or
study that are not reflected in Company's prior disclosures, and
the fact that trial or study results or subsequent analyses may be
subject to differing interpretations by regulatory agencies, the
inability to successfully develop the Company's product candidates
or receive necessary regulatory approvals, inability to make
product candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for
the year ended December 31, 2012. Investors are cautioned not to
place undue reliance on any forward-looking statements that speak
only as of the date of this news release. The Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in its expectations.
Contacts: LHA Anne Marie Fields Senior Vice President
212-838-3777 afields@lhai.com Bruce Voss Managing Director
310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024